NTRK1 and neuroblastoma: Recent advances in the molecular mechanisms involved in NB pathogenesis and progression has resulted in the development of novel targeted therapies against activated ALK and Trk oncogenes, with the aim of improving the quality of life and overall survival of patients with advanced stage refractory and metastatic NB, and are currently in clinical trials [33].